Comparison of ConvNeXt-S and DeiT-S in terms of correlation between ImageNet-1K accuracy and Giga floating point operations per second (GFLOPs). by Sirikorn Sangchocanonta (20917797)

Subjects:

The process of the proposed glaucoma classification method. by Sirikorn Sangchocanonta (20917797)

Subjects:

Minimum data set used in the article. by Shizhen Xu (4474321)

“…The average total phosphorus (TP) content in cropland soil was slightly higher than in forestland and significantly higher than in grassland. The weaker carbon-sequestration capacity of cropland soil resulted in notably lower C:N (10.13) and C:P (47.38) ratios compared to forestland and grassland. …”

Concentrations of C, N, and P in time change. by Shizhen Xu (4474321)

“…The average total phosphorus (TP) content in cropland soil was slightly higher than in forestland and significantly higher than in grassland. The weaker carbon-sequestration capacity of cropland soil resulted in notably lower C:N (10.13) and C:P (47.38) ratios compared to forestland and grassland. …”

Supplementary file 1_Clinical utility of the PBAC score in quantifying treatment response to hysteroscopy: a retrospective observational study.docx by Ömer Faruk Öz (22702202)

“…Data were analyzed using SPSS version 26, and p < 0.05 was considered statistically significant.</p>Results<p>Of the 327 patients included in the study, 91.1% had a baseline PBAC score ≥100, which significantly decreased following hysteroscopy (mean reduction: 393 points; p < .001). …”

Supplementary file 2_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”

Supplementary file 5_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”

Supplementary file 3_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”

Supplementary file 1_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”

Supplementary file 4_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”

Supplementary file 6_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.docx by Yi-Chang Zhao (14080107)

“…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”

Data Sheet 1_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.pdf by Zemin Liu (224306)

“…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”

Image 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

Table 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

Image 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

Table 7_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

Table 6_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

Table 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

Table 4_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

Table 3_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)